Introduction:
Liraglutide, a glucagon-like peptide 1 receptor agonist (GLP-1) utilized for management of type 2 diabetes mellitus, has been associated with reduced risk of cardiovascular events. However, it is also associated with increased heart rate and reduced heart rate variability. In this study, we investigate the effect of liraglutide in patients with atrial fibrillation (AF).